Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4816-4824

  Caldes A ^a   Colom, H ^b   Armendariz, Y ^a   Garrido, M J ^c   Troconiz, I F ^c   Gil Vernet, S ^a   Lloberas, N ^a   Pou, L ^d   Peraire, C ^b   Grinyo J M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIMULATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES;

EID: 70350318141     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00085-09     Document Type: Article

References (29)

1. Asberg, A., A. Humar, H. Rollag, A. G. Jardine, H. Mouas, M. D. Pescovitz, D. Sgarabotto, M. Tuncer, I. L. Noronha, and A. Hartmann. 2007. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7:2106-2113.
2. Avery, R. K. 2007. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved? Am. J. Transplant. 7:2062-2063.
3. Beal, S. L., and L. B. Sheiner (ed.). 1992. NONMEM VI user's guide. Globomax LLC, Hanover, MD.
4. Brown, F., L. Banken, K. Saywell, and I. Arum. 1999. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin. Pharmacokinet. 37:167-176.
5. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
6. Crumpacker, C. S. 1996. Ganciclovir. N. Engl. J. Med. 335:721-729.
7. Cvetkovic, R. S., and K. Wellington. 2005. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65:859-878.
8. Czock, D., C. Scholle, F. M. Rasche, D. Schaarschmidt, and F. Keller. 2002. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin. Pharmacol. Ther. 72:142-150.
9. Dubois, D., and E. Dubois. 1916. A formula to estimate the approximate surface area if height and weight are known. Arch. Intern. Med. 17:863-871.
10. Efron, B. 1979. Bootstrap methods: another look at the jacknife. Ann. Stat. 7:1-26.
11. Einsele, H., P. Reusser, M. Bornhauser, P. Kalhs, G. Ehninger, H. Hebart, Y. Chalandon, N. Kroger, B. Hertenstein, and F. Rohde. 2006. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107:3002-3008.
12. Ette, E. I., and T. M. Ludden. 1995. Population pharmacokinetic modeling: the importance of informative graphics. Pharm. Res. 12:1845-1855.
13. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
14. Karlsson, M. O., E. N. Jonsson, C. G. Wiltse, and J. R. Wade. 1998. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J. Pharmacokinet. Biopharm. 26:207-246.
15. Karlsson, M. O., and R. M. Savic. 2007. Diagnosing and model diagnostics. Clin. Pharmacol. Ther. 82:17-20.
16. Karlsson, M. O., and L. B. Sheiner. 1993. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750.
17. Kerbusch, T., P. A. Milligan, and M. O. Karlsson. 2004. Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic- phamacodynamic data. Br. J. Clin. Pharmacol. 57:170-180.
18. Limaye, A. P. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35:866-872.
19. Lindbom, L., P. Pihlgren, and N. Jonsson. 2005. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257.
20. McGavin, J. K., and K. L. Goa. 2001. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61:1153-1183.
21. Pescovitz, M. D., J. Rabkin, R. M. Merion, C. V. Paya, J. Pirsch, R. B. Freeman, J. O'Grady, C. Robinson, Z. To, K. Wren, L. Banken, W. Buhles, and F. Brown. 2000. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44:2811-2815.
22. Pou, L., F. Campos, B. Almirante, et al. 1993. A rapid liquid chromatographic (HPLC) method for determination of ganciclovir in serum, p. 183-186. In M. M. Galteau, G. Siest, and J. Henny (ed.), Biology prospective. Comptes rendís du 8ieme Coloque de Pont-a-Mousson. John Libbey Eurotext, Paris, France.
23. Savic, R. M., D. M. Jonker, T. Kerbusch, and M. O. Karlsson. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726.
24. Tolkoff-Rubin, N. E., and R. H. Rubin. 1999. The impact of cytomegalovirus infection on graft function and patient outcome. Graft 2:S101-S103.
25. Vancíková, Z., and P. Dvorak. 2001. Cytomegalovirus infection in immunocompetent and immunocompromised individuals: a review. Curr. Drug Targets Immune Endocr. Metabol. Disord. 1:179-187.
26. Wiltshire, H., S. Hirankarn, C. Farrell, C. Paya, M. D. Pescovitz, A. Humar, E. Dominguez, K. Washburn, E. Blumberg, B. Alexander, R. Freeman, and N. Heaton. 2005. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin. Pharmacokinet. 44:495-507.
27. Wiltshire, H., C. V. Paya, M. D. Pescovitz, A. Humar, E. Dominguez, K. Washburn, E. Blumberg, B. Alexander, R. Freeman, N. Heaton, and K. P. Zuideveld. 2005. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79:1477-1483. (Pubitemid 40847577)
28. Winston, D. J., L. R. Baden, D. A. Gabriel, C. Emmanouilides, L. M. Shaw, W. R. Lange, and V. Ratanatharathorn. 2006. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol. Blood Marrow Transplant. 12:635-640.
29. Yuen, G. J., G. L. Drusano, C. Fletcher, E. Capparelli, J. D. Connor, J. P. Lalezari, L. Drew, S. Follansbee, D. Busch, M. Jacobson, et al. 1995. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob. Agents Chemother. 39:2350-2352.